<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39438096</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial.</ArticleTitle><Pagination><StartPage>e081790</StartPage><MedlinePgn>e081790</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e081790</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2023-081790</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people with COVID-19.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective, multicentre, double-blind, placebo-controlled trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Ten acute care hospitals in India.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Adults &lt;65 years old intended for hospital admission with moderate/severe COVID-19 disease (respiratory rate ≥24 breaths per minute or oxygen saturation ≤93% on room air).</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">DMX-200 120 mg two times per day, or placebo, on background of titratable candesartan commencing at 4 mg two times per day, for 28 days.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary endpoint was COVID-19 disease severity on a modified WHO Clinical Progression Scale (WHO scale) on day 14. Secondary outcomes included the WHO scale at days 28, 60, 90 and 180; intensive care unit (ICU) admission, respiratory failure or death within 28 days; length of hospitalisation; and requirement for ventilatory support or dialysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between December 2021 and August 2022, 518 people were screened, with 49 randomised to DMX-200 or placebo on a background of candesartan. The study was terminated early due to recruitment barriers, including an external requirement to restrict enrolment to adults &lt;65 years old, contributing to a 91% screen failure rate. The median WHO Clinical Progression Scale (WHO scale) score at day 14 for both groups was 1 (IQR 1-1), indicating most participants were discharged with no limitations on activities by this time. Formal comparison was not performed due to the small sample size. One participant receiving DMX-200 died of COVID-19 disease progression. No participants required ICU admission, ventilation or dialysis. Median length of hospitalisation in both groups was 6 days (IQR 6-7 days). WHO scale scores were similar at 28, 60, 90 and 180 days.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Due to recruitment barriers, the study was unable to determine whether DMX-200 improves clinical outcomes in people with COVID-19.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT05122182.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Hara</LastName><ForeName>Daniel Vincent</ForeName><Initials>DV</Initials><Identifier Source="ORCID">0000-0001-6066-8860</Identifier><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia daniel.ohara@sydney.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Renal Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassi</LastName><ForeName>Abhinav</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The George Institute for Global Health India, New Delhi, Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilcox</LastName><ForeName>Arlen</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4128-1796</Identifier><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jha</LastName><ForeName>Vivekanand</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>The George Institute for Global Health India, New Delhi, Delhi, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Imperial College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rathore</LastName><ForeName>Vinay</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-4315-5072</Identifier><AffiliationInfo><Affiliation>All India Institute of Medical Sciences, Raipur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Cruz</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Government Medical College and Hospital, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snelling</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Totterdell</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health, The University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bangi</LastName><ForeName>Ashpak</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jivanrekha Multispecialty Hospital, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Manish Kumar</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Maharaja Agrasen Superspecialty Hospital, Jaipur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Renal Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kolling Institute of Medical Research, St Leonards, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burrell</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Breathing and Sleep, Heidelberg, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Central Clinical School, The University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotwal</LastName><ForeName>Sradha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Renal and Metabolic Division, George Institute for Global Health, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Prince of Wales Hospital and Community Health Services, Randwick, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faridah Syed Omar</LastName><ForeName>Sharifah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jardine</LastName><ForeName>Meg</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Concord Repatriation General Hospital, Concord, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CLARITY 2.0 trial investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05122182</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>S8Q36MD2XX</RegistryNumber><NameOfSubstance UI="C081643">candesartan</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047228">Angiotensin II Type 1 Receptor Blockers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001562" MajorTopicYN="Y">Benzimidazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001713" MajorTopicYN="Y">Biphenyl Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013777" MajorTopicYN="Y">Tetrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047228" MajorTopicYN="N">Angiotensin II Type 1 Receptor Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">randomized controlled trial</Keyword></KeywordList><CoiStatement>Competing interests: This work was an investigator-initiated study that received financial support from Dimerix Bioscience Pty Ltd who manufacture DMX-200.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Bathla</LastName><ForeName>Nikita</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diamante</LastName><ForeName>Katrina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mercade</LastName><ForeName>Gerard Estivill</ForeName><Initials>GE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xie</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nair</LastName><ForeName>Aishwarya</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decaria</LastName><ForeName>Annelise</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abignano</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jindal</LastName><ForeName>Atul</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siddiqui</LastName><ForeName>Sabah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Suprava</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sahu</LastName><ForeName>Anjulata</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaikh</LastName><ForeName>Yasmeen</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jain</LastName><ForeName>Madhavender</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soni</LastName><ForeName>Kapil</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kanje</LastName><ForeName>Shivam R</ForeName><Initials>SR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vimal</LastName><ForeName>Sanjeev Kumar</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalyan Chakravarthy</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sathish Babu</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheema</LastName><ForeName>Yuvraj Singh</ForeName><Initials>YS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moni</LastName><ForeName>Merlin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nair</LastName><ForeName>Sivapriya G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haynes</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kang</LastName><ForeName>Gagandeep</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thwaites</LastName><ForeName>Guy</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Staplin</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heritier</LastName><ForeName>Stephane</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39438096</ArticleId><ArticleId IdType="pmc">PMC11499840</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2023-081790</ArticleId><ArticleId IdType="pii">bmjopen-2023-081790</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061–9. doi: 10.1001/jama.2020.1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YT, Wang YC, Lee HL, et al. Monocyte Chemoattractant Protein-1, a Possible Biomarker of Multiorgan Failure and Mortality in Ventilator-Associated Pneumonia. Int J Mol Sci. 2019;20:2218. doi: 10.3390/ijms20092218.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20092218</ArticleId><ArticleId IdType="pmc">PMC6539645</ArticleId><ArticleId IdType="pubmed">31064097</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CK, Lam CWK, Wu AKL, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136:95–103. doi: 10.1111/j.1365-2249.2004.02415.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2004.02415.x</ArticleId><ArticleId IdType="pmc">PMC1808997</ArticleId><ArticleId IdType="pubmed">15030519</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271–80. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature New Biol. 2020;581:215–20. doi: 10.1038/s41586-020-2180-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung ML, Teng JLL, Jia L, et al. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell. 2021;184:2212–28. doi: 10.1016/j.cell.2021.02.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.053</ArticleId><ArticleId IdType="pmc">PMC7923941</ArticleId><ArticleId IdType="pubmed">33713620</ArticleId></ArticleIdList></Reference><Reference><Citation>V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19:155–70. doi: 10.1038/s41579-020-00468-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId><ArticleId IdType="pmc">PMC7592455</ArticleId><ArticleId IdType="pubmed">33116300</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–9. doi: 10.1038/nm1267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1267</ArticleId><ArticleId IdType="pmc">PMC7095783</ArticleId><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoub MA, Zhang Y, Kelly RS, et al. Functional interaction between angiotensin II receptor type 1 and chemokine (C-C motif) receptor 2 with implications for chronic kidney disease. PLoS One. 2015;10:e0119803. doi: 10.1371/journal.pone.0119803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0119803</ArticleId><ArticleId IdType="pmc">PMC4373786</ArticleId><ArticleId IdType="pubmed">25807547</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan DP, Coy JW, Chahal KK, et al. The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment. J Immunol. 2019;202:3087–102. doi: 10.4049/jimmunol.1800619.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1800619</ArticleId><ArticleId IdType="pmc">PMC6504574</ArticleId><ArticleId IdType="pubmed">30971441</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham HMA, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015;38:33–54. doi: 10.1007/s40264-014-0239-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0239-7</ArticleId><ArticleId IdType="pmc">PMC4303500</ArticleId><ArticleId IdType="pubmed">25416320</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayama C, Suzuki H, Ito M, et al. Propagermanium: a nonspecific immune modulator for chronic hepatitis B. J Gastroenterol. 2003;38:525–32. doi: 10.1007/s00535-003-1098-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-003-1098-7</ArticleId><ArticleId IdType="pubmed">12825127</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384:693–704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardine MJ, Kotwal SS, Bassi A, et al. Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. BMJ. 2022;379:e072175. doi: 10.1136/bmj-2022-072175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072175</ArticleId><ArticleId IdType="pmc">PMC9667467</ArticleId><ArticleId IdType="pubmed">36384746</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Wang J, Liu C, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med. 2020;26:97. doi: 10.1186/s10020-020-00230-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-020-00230-x</ArticleId><ArticleId IdType="pmc">PMC7594996</ArticleId><ArticleId IdType="pubmed">33121429</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29:313–26. doi: 10.1089/jir.2008.0027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2008.0027</ArticleId><ArticleId IdType="pmc">PMC2755091</ArticleId><ArticleId IdType="pubmed">19441883</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimerix reports positive phase 2 study results of DMX-200 in diabetic kidney disease [press release] 2020.</Citation></Reference><Reference><Citation>Lawler PR, Derde LPG, van de Veerdonk FL, et al. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA. 2023;329:1183–96. doi: 10.1001/jama.2023.4480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.4480</ArticleId><ArticleId IdType="pmc">PMC10326520</ArticleId><ArticleId IdType="pubmed">37039790</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>